Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment

Inclusion Criteria: * Patient aged 18 or older undergoing neoadjuvant chemotherapy regimens including taxane and/or anthracycline for breast cancer. * Patient aged 18 or older undergoing any chemotherapy regimen for pancreatic cancer * Have 'high metabolic risk(either pre-diabetes, obesity, or well-controlled diabetes) defined as either: * Pre-diabetes and/or obesity group: one or more of known HbA1c 5.7-6.5%, fasting glucose \> 100 mg/dL, or BMI \> 30 * Well-controlled diabetes: Known HbA1c \< 7.5 on lifestyle alone or up to one oral antidiabetic agent * Any patient undergoing treatment for pancreatic adenocarcinoma on either no antidiabetic agent or up to one oral antidiabetic agent Exclusion Criteria: * Patients with type 1 diabetes, a history of hospitalization for either hyperglycemia or ketoacidosis, a history of hypoglycemia requiring hospitalization, rashes or other skin reactions that would preclude placement of the CGM * Use of anticoagulants or antiplatelet agents other than aspirin * Platelet count \< 50 K/μL within 60 days prior to enrollment.